What is HC Wainwright's Forecast for ALNY FY2024 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued on Monday, November 4th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings per share of ($2.24) for the year, up from their prior forecast of ($2.31). HC Wainwright currently has a "Buy" rating and a $400.00 target price on the stock. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals' Q4 2024 earnings at ($0.71) EPS, FY2026 earnings at $9.23 EPS, FY2027 earnings at $19.05 EPS and FY2028 earnings at $22.41 EPS.

A number of other brokerages have also recently weighed in on ALNY. Cantor Fitzgerald restated a "neutral" rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a "neutral" rating in a research report on Monday, August 26th. Morgan Stanley lifted their price objective on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an "equal weight" rating in a research report on Friday, July 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $294.50.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $0.79 during midday trading on Thursday, hitting $272.22. 607,374 shares of the stock were exchanged, compared to its average volume of 872,402. The stock's 50-day moving average price is $274.17 and its 200-day moving average price is $229.04. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a market cap of $35.11 billion, a price-to-earnings ratio of -104.20 and a beta of 0.39. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company's revenue for the quarter was down 33.3% on a year-over-year basis. During the same period last year, the firm posted $1.15 EPS.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its stake in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 143 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $26,000. Huntington National Bank grew its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Finally, Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $30,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.